设为主页 | 加入收藏夹 | English
服务热线:Tel:+86-755-3282 5499
Whatsapp/Cell: +86-136 3280 3610
Skype: melissaxu2013
QQ: 2542654757
E-Mail: melissa.xu@x-waymedical.com
本站首页 企业简介 新闻动态 产品展示 在线订购 人才招聘 资料下载
联系方式
  产品类别
  Interventional Products
球囊压力泵
Introducer sheath catheter
导丝/诊断导管
配件及附件
  麻醉及重症监护产品
CT MRI DSA 高压注射器针筒套装
麻醉类产品
  医用手术工具器械
内窥镜手术器械
  高分子小配件
甘素帽
无针接头
延长管 连接管
  联系我们
深圳艾克斯维医疗科技有限公司
联系人: 徐小姐
电话: +86-755-3282 5499
手机: 136-3280-3610
QQ: 2542 654757
E-Mail: melissa.xu@x-waymedical.com
地址: 广东省深圳市龙岗区布吉镇甘坑村金湖工业园南座3楼
  新闻动态

FDA Approves World’s First Drug-Coated Angioplasty Balloon Catheter

FDA announced in October that it approved the world’s first drug-coated angioplasty balloon catheter to treat peripheral artery disease.

The Lutonix 035 drug-coated balloon (DCB) is made by Minnesota-based Lutonix, which C.R. Bard purchased in December 2011 for an upfront $225 million with $100 million due upon FDA approval of the device. The product has been available in Europe since 2012. The greenlight comes after an FDA panel unanimously recommended the product’s approval in June.

20150114独家

In the United States, this is the first drugcoated balloon used to reopen arteries in the thigh and knee when they become narrowed or blocked because of peripheral artery disease (PAD), according a news release. People with PAD suffer leg pain, and may lead to skin ulcers and gangrene.

“In line with Bard’s commitment to delivering products that improve patient care, we are proud to offer another Bard first-of-its-kind innovation that expands therapy options for this painful, progressive and debilitating disease,” Timothy M. Ring, chairman and CEO of C. R. Bard, said in a news release. “The Lutonix 035 DCB gives clinicians another option as they seek to provide prolonged patency to patients confronted with femoropopliteal occlusive disease.” 

The drug-eluting balloon is coated externally with paclitaxel, a drug that has the potential to help prevent the arteries from being blocked again after the procedure.

During the procedure, the blocked artery is first partially opened with a traditional angioplasty balloon sans the drug. Thereafter, the Lutonix DCB is used to fully open the narrowed portion of the artery. This allows the drug to be applied to the artery wall.

In a pivotal, single-blind, randomized multicenter study conducted in the United States and Europe that enrolled 476 patients, 65.2% of participants treated with Lutonix DCB did not have a narrowing of the arteries (restenosis) compared with 52.6% of the control group after 12 months.

By : Arundhati Parmar,<MDDI>

 

 

  友情链接
本站首页 企业简介 新闻动态 产品展示 在线订购 人才招聘 资料下载
联系方式

深圳艾克斯维医疗科技有限公司 联系人: 徐小姐 电话: +86-755-3282 5499 手机:+86 136-3280-3610 Skype: melissaxu2013 Whatsapp: +86-136 3280 3610 地址: 深圳市龙岗区布吉镇金湖工业园南座3楼

  技术支持:科正网络